Clinical Trial Update: Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a detoxified J5 core glycolipid/Group B meningococcal outer membrane protein vaccine for Gram-negative bacterial sepsis, administered w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Sepsis

Drugs mentioned

• CpG ODN 7909 Adjuvant (CpG oligodeoxynucleotide 7909)
• Detoxified J5 Core Glycolipid/Group B Meningococcal Outer Membrane Protein Vaccine (Detoxified J5 core glycolipid/Group B meningococcal outer membrane protein vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Bacterial Sepsis | Phase 1 | Status: TERMINATED